BioSpace News Archive

Developments to be Shared by Dr. Jack Reich, Director, Dr. Bankole A. Johnson, Chief Medical Officer, William B. Stilley, III, Chief Executive Officer, and Joseph A. M. Truluck, Chief Financial Officer

Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported new data demonstrating that the blueberry derived compound pterostilbene possesses numerous brain protective and potentially brain regenerative activities.

Health Canada has authorized with conditions the drug remdesivir manufactured by Gilead Sciences Canada, Inc. for the treatment of patients with severe symptoms of COVID-19 who have pneumonia and require extra oxygen to help them breathe.

- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN, July 28, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) announced today that the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization appli

A study leveraging TriNetX, the global health research network that optimizes clinical research and enables discoveries through the generation of real-world evidence (RWE), found that cancer patient encounters fell precipitously in January to April 2020 compared to the same months in 2019.

Impressio Inc. and MedShape Inc. have been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $250,000 to conduct research and development (R&D) work on a new surgical treatment

Sixth acquisition in just over a year deepens firm’s value, access and pricing insights, policy, communications, marketing and consulting capabilities

bioAffinity Technologies , a privately held biotech company, today announced it has closed a non-brokered, secured convertible note (“Note”) financing for proceeds of $5,000,000.00 (the “Offering”). The proceeds from the Note are funding operations to advance the Company’s non-invasive CyPath® Lung cancer test and therapeutic research and development of novel drug candidates for the selective treatment of multiple cancers.

Matrix Medical Network has formed a strategic committee of trusted clinical advisors that includes distinguished industry experts whose focus will be to guide the strategy and clinical practices of Matrix’s COVID-19 support programs

BioTheryX, Inc., a clinical stage biotechnology company harnessing the power of protein modulation to treat difficult diseases, today announced it has closed a $35 million Series D financing. The round was led by MSD Partners, L.P. “We are pleased to have closed this financing that will enable us to accelerate expansion of our ongoin